Shionogi Reports Promising Results on Its COVID-19 Drug Candidate
Shionogi said that its investigational COVID-19 treatment ensitrelvir fumaric acid has shown promising results in a phase 3 clinical trial.
The investigational drug is a 3CL protease inhibitor — the main protease found in coronaviruses — being evaluated as a potential antiviral treatment for COVID-19 infection.
Study results demonstrated that the drug candidate significantly reduced the time to resolution of five COVID-19 symptoms compared with placebo. The five symptoms were stuffy or runny nose, sore throat, cough, feeling hot or feverish and low energy or tiredness.
The study was conducted in Asia. The investigational treatment hasn’t been authorized or approved anywhere in the world.